Effects of somatotropin on the conceptus, uterus, and ovary during maternal recognition of pregnancy in cattle.
Effects of recombinant bovine somatotropin (rbST) on ovarian and uterine function and the production of components of the insulin-like growth factor (IGF) system were examined during the period of maternal recognition of pregnancy in cattle. Lactating dairy cows were treated with 25 mg/d rbST (n = 8) or saline (n = 8) for 16 d after estrus. Ovaries, uteri, and conceptuses were collected on Day 17 after estrus. The length (millimeters) of the conceptus was recorded. The concentration of IGF-I and the content of IGF-binding proteins (BP) in uterine flushings were determined. Corpora lutea (CL) were weighed, and the number of follicles (> or = 2 mm in diameter) were counted. Follicular fluid from the largest and second-largest follicles was assayed for the concentration of IGF-I, IGFBP, progesterone, and estradiol. The length of the conceptus and the total amount of IGF-I in uterine fluid were similar for rbST and control. Recombinant bST increased 1) the weight of the CL, 2) the number of largest follicles (10 to 15 mm in diameter), 3) the concentration of IGF-I in the follicular fluid, 4) the follicular fluid content of IGFBP of the largest estrogenic follicle, and 5) the quantity of IGFBP in uterine flushings. The concentration of progesterone in the follicular fluid tended to be increased in rbST-treated cows, whereas the concentration of estradiol was similar to that of control cows. The concentration of progesterone in plasma was similar for rbST compared with control. In conclusion, the administration of rbST in lactating dairy cows for 16 d after estrus did not alter the growth of the conceptus collected on Day 17. The greatest responses to rbST were found within the ovary, where rbST increased the weight of the CL and altered the amount of IGF-I and IGFBP in the follicular fluid.
Lucy
M C
MC
Monsanto Co., St. Louis, Missouri 63198, USA.
Thatcher
W W
WW
Collier
R J
RJ
Simmen
F A
FA
Ko
Y
Y
Savio
J D
JD
Badinga
L
L
D000818:Animals; D002352:Carrier Proteins / Q000032:analysis / Q000097:blood; D002417:Cattle / Q000378:metabolism / Q000502:physiology*; D003338:Corpus Luteum / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D004958:Estradiol / Q000032:analysis / Q000097:blood; D005260:Female; D005333:Fetus / Q000187:drug effects* / Q000502:physiology; D015571:Follicular Fluid / Q000737:chemistry / Q000378:metabolism; D013006:Growth Hormone / Q000494:pharmacology*; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D007774:Lactation / Q000502:physiology; D006080:Ovarian Follicle / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010053:Ovary / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000502:physiology*; D011374:Progesterone / Q000032:analysis / Q000097:blood; D011994:Recombinant Proteins / Q000494:pharmacology; D014599:Uterus / Q000737:chemistry / Q000187:drug effects* / Q000502:physiology
D002352:Carrier Proteins; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D011374:Progesterone; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone